Feed/Companies/Allotera Therapeutics

Allotera Therapeutics

As of 14 Oct 2026, Allotera Therapeutics has raised $115M across 1 verified round on record; latest: $115 million Series C led by Fidelity Management & Research Company, announced 27 Aug 2025.

BUILT ON

Visit site

Allotera Therapeutics develops allogeneic T-cell therapies targeted at treating various types of blood cancers like leukemia and lymphoma.

alloteratx.comLinkedInSt. Louis, MissouriBiotech

LATEST ROUND

Series C

$115M · 2025-08-27

RAISED ON RECORD · USD

$115M

across 1 verified round

INVESTORS

1 lead

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series CSeries C funding round

$115M · 2025-08-27

[ HISTORY ]

led by Fidelity Management & Research Company

Round	Amount	Announced	Lead	Buzz
Series C Series C funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$115M	2025-08-27	Fidelity Management & Research Company	No recent discussion
1 source [ VERIFIED ] read against 1 source The source describes this as the first close; any later close is not included. Published by hand (packgene.com): "Wugen, a clinical-stage biotechnology company, announced today the first close of a $115 million Series C funding round, led by existing investor Fidelity Management & Research Company.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it

Allotera Therapeutics

Company

Rounds

Sources

Profile

Investors

Allotera Therapeutics

Rounds

Profile

Sources

Series C$115M2025-08-271 source

Investors

Series C$115M2025-08-271 investor